Last reviewed · How we verify
Cholecalciferol 100.000 UI administration
Cholecalciferol (vitamin D3) is converted in the body to its active form, calcitriol, which regulates calcium and phosphate homeostasis and modulates immune function.
Cholecalciferol (vitamin D3) is converted in the body to its active form, calcitriol, which regulates calcium and phosphate homeostasis and modulates immune function. Used for Vitamin D deficiency in chronic kidney disease patients, Secondary hyperparathyroidism management, Mineral bone disorder in renal disease.
At a glance
| Generic name | Cholecalciferol 100.000 UI administration |
|---|---|
| Sponsor | Institut Phoceen de Nephrologie |
| Drug class | Vitamin D analog / Nutritional supplement |
| Target | Vitamin D receptor (VDR) |
| Modality | Small molecule |
| Therapeutic area | Nephrology / Mineral metabolism / Immunology |
| Phase | Phase 3 |
Mechanism of action
Cholecalciferol is a fat-soluble vitamin that undergoes hydroxylation in the liver and kidneys to form the active hormone calcitriol (1,25-dihydroxyvitamin D3). The active metabolite binds to vitamin D receptors in target tissues, promoting intestinal calcium and phosphate absorption, regulating bone mineralization, and modulating immune cell differentiation and function. This mechanism makes it therapeutically relevant for conditions involving mineral metabolism disorders and potentially immune-mediated diseases.
Approved indications
- Vitamin D deficiency in chronic kidney disease patients
- Secondary hyperparathyroidism management
- Mineral bone disorder in renal disease
Common side effects
- Hypercalcemia
- Hyperphosphatemia
- Nausea
- Vomiting
- Constipation
Key clinical trials
- Efficacy of Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of MS After a Clinically Isolated Syndrome (PHASE3)
- Does Correction of 25 OH-VITAmin D With Cholecalciferol Supplementation Increase Muscle Strength in hemoDIALysis Patients? (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: